Cytokinetics Announces Closing of Public Offering of Common Stock
28 Maio 2024 - 5:00PM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the
closing of its previously announced underwritten public offering of
9,803,922 shares of its common stock at a price to the public
of $51.00 per share. The gross proceeds
to Cytokinetics from the offering, before offering
expenses payable by Cytokinetics, were approximately $500
million.
J.P. Morgan, Goldman Sachs & Co. LLC and
Morgan Stanley acted as joint book-running managers for the
offering.
The securities described above were offered
by Cytokinetics pursuant to a shelf registration
statement (including a base prospectus) filed on November 18,
2022 with the Securities and Exchange
Commission (SEC), which has become automatically effective. A
final prospectus supplement and accompanying prospectus relating to
the offering have been filed with the SEC and can be
accessed for free on the SEC’s website
at http://www.sec.gov. Copies of the final prospectus
supplement and accompanying prospectus relating to the offering may
be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York
11717, by email at prospectus-eq_fi@jpmchase.com and
postsalemanualrequests@broadridge.com; Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, New
York 10282, by telephone at (866) 471-2526, or by email at
Prospectus-ny@ny.email.gs.com; or Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, New York 10014, by telephone at 866-718-1649 or by email at
prospectus@morganstanley.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Contact:CytokineticsDiane WeiserSenior Vice President, Corporate
Affairs(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Cytokinetics (NASDAQ:CYTK)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024